Mark J. Foley, Director at Revance Therapeutics, Inc. (RVNC), bought 20,000 shares at $26.95 ($539K) on 2017-11-07, disclosed to the SEC on 2017-11-09.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.95 | 19,500 | $526K | 97.5% |
| 2 | $27.45 | 500 | $14K | 2.5% |
| Total | $26.96 avg | 20,000 | $539K | 100% |
| Filing → |
| GKOS | SELL | 2024-02-26 | $847K | — | Filing → |
| RVNC | SELL | 2023-08-04 | $1.2M | — | Filing → |
| RVNC | SELL | 2023-07-05 | $1.3M | — | Filing → |